We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Read MoreHide Full Article
Key Takeaways
Tempus AI's Q2 loss was 22 cents per share, beating estimates by 4.4%.
TEM's Q2 revenues jumped 89.6% year over year to $314.6 million, topping expectations.
TEM's Genomics sales grew 115.3%, fueled by oncology and hereditary testing volume gains.
Tempus AI, Inc. (TEM - Free Report) reported a second-quarter 2025 adjusted loss of 22 cents per share, narrower than the Zacks Consensus Estimate by 4.35%.
GAAP loss per share was 25 cents compared with a loss of $6.86 year over year.
TEM’s Q2 Revenues
Revenues totaled $314.6 million, which beat the Zacks Consensus Estimate by 5.12%. The top line surged 89.6% on a year-over-year basis.
Following the announcement, shares of Tempus AI rose 2.2% in the pre-market trading today.
Detailed Breakdown of TEM’s Q2 Revenues
In the second quarter, Genomics contributed $193.8 million in revenues, up 115.3% year over year.
Within this, Oncology testing (legacy Tempus clinical) revenues were $133.2 million, up 32.9% year over year. This was supported by approximately 26% volume growth in the second quarter.
Hereditary testing (legacy Ambry Genetics) contributed $97.3 million in revenues, up 33.6% year over year on a pro-forma basis. Volume growth was approximately 32%.
The Data and Services product line reported sales of $72.8 million, up 35.7% year over year. This was driven by Insights (data licensing), which grew 40.7% year over year.
TEM’s Margin Performance
The gross profit in the quarter totaled $195 million, up 158.3% from the year-ago quarter’s level. The adjusted gross margin expanded 1649 bps to 62% despite a 32.2% rise in the cost of revenues (genomics, data and services).
Total adjusted operating expenses were $256.8 million, down 57.8% from the year-ago quarter’s level.
TEM’s Liquidity Position
At the end of the second quarter of 2025, the company had cash and cash equivalents of $186.3 million compared with $151.6 million at the end of the first quarter.
Cumulative net cash used in operating activities at the end of the second quarter was $61.46 million compared with an outflow of $198.5 million in the prior year.
Tempus AI’s Full-Year Outlook
The company provided updated guidance for 2025. Full-year revenues are expected to be approximately $1.26 billion (earlier $1.25 billion) for the consolidated Tempus and Ambry Genetics business, indicating nearly 82% annual growth. The Zacks Consensus Estimate for TEM’s revenues in 2025 currently stands at $1.24 billion.
Adjusted EBITDA for the year is expected to be $5 million, an improvement of approximately $110 million over 2024.
Our Take on TEM Stock
Tempus AI ended the second quarter of 2025 with better-than-expected earnings and revenues. The company witnessed a significant reacceleration of its clinical volumes. The company had several milestones in the second quarter, including the introduction of Tempus xM for treatment and response monitoring, a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors. It also extended the Tempus Next care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. Furthermore, raised revenue guidance for the year bodes well for the stock.
TEM’s Zacks Rank and Key Picks
Tempus AI currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Key Takeaways
Tempus AI, Inc. (TEM - Free Report) reported a second-quarter 2025 adjusted loss of 22 cents per share, narrower than the Zacks Consensus Estimate by 4.35%.
GAAP loss per share was 25 cents compared with a loss of $6.86 year over year.
TEM’s Q2 Revenues
Revenues totaled $314.6 million, which beat the Zacks Consensus Estimate by 5.12%. The top line surged 89.6% on a year-over-year basis.
Following the announcement, shares of Tempus AI rose 2.2% in the pre-market trading today.
Detailed Breakdown of TEM’s Q2 Revenues
In the second quarter, Genomics contributed $193.8 million in revenues, up 115.3% year over year.
Within this, Oncology testing (legacy Tempus clinical) revenues were $133.2 million, up 32.9% year over year. This was supported by approximately 26% volume growth in the second quarter.
Tempus AI, Inc. Price, Consensus and EPS Surprise
Tempus AI, Inc. price-consensus-eps-surprise-chart | Tempus AI, Inc. Quote
Hereditary testing (legacy Ambry Genetics) contributed $97.3 million in revenues, up 33.6% year over year on a pro-forma basis. Volume growth was approximately 32%.
The Data and Services product line reported sales of $72.8 million, up 35.7% year over year. This was driven by Insights (data licensing), which grew 40.7% year over year.
TEM’s Margin Performance
The gross profit in the quarter totaled $195 million, up 158.3% from the year-ago quarter’s level. The adjusted gross margin expanded 1649 bps to 62% despite a 32.2% rise in the cost of revenues (genomics, data and services).
Total adjusted operating expenses were $256.8 million, down 57.8% from the year-ago quarter’s level.
TEM’s Liquidity Position
At the end of the second quarter of 2025, the company had cash and cash equivalents of $186.3 million compared with $151.6 million at the end of the first quarter.
Cumulative net cash used in operating activities at the end of the second quarter was $61.46 million compared with an outflow of $198.5 million in the prior year.
Tempus AI’s Full-Year Outlook
The company provided updated guidance for 2025. Full-year revenues are expected to be approximately $1.26 billion (earlier $1.25 billion) for the consolidated Tempus and Ambry Genetics business, indicating nearly 82% annual growth. The Zacks Consensus Estimate for TEM’s revenues in 2025 currently stands at $1.24 billion.
Adjusted EBITDA for the year is expected to be $5 million, an improvement of approximately $110 million over 2024.
Our Take on TEM Stock
Tempus AI ended the second quarter of 2025 with better-than-expected earnings and revenues. The company witnessed a significant reacceleration of its clinical volumes. The company had several milestones in the second quarter, including the introduction of Tempus xM for treatment and response monitoring, a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors. It also extended the Tempus Next care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. Furthermore, raised revenue guidance for the year bodes well for the stock.
TEM’s Zacks Rank and Key Picks
Tempus AI currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.